Table 1 Percentage of patients with supraventricular tachycardia (SVT), ventricular tachycardia (VT) or increase in premature ventricular complexes (PCV) after receiving levosimendan or placebo
From: Effects of levosimendan on cardiac arrhythmia in patients with severe heart failure
| SVT | VT | Increase in PCV | |
|---|---|---|---|
| Levosimendan | 5% | 12% | 8% |
| Placebo | 5% | 15% | 9% |